|
If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||||||
  Clinical and Experimental DermatologyVolume 34 Issue 7, Pages 784 - 788 Published Online: 27 Apr 2009 Journal compilation © 2010 British Association of Dermatologists An Official Journal of the British Association of Dermatologists
Abstract | References | Full Text: HTML, PDF (Size: 106K) | Related Articles | Citation Tracking  Clinical dermatology • Original article Adalimumab treatment for severe recalcitrant chronic plaque psoriasis Conflict of interest: Professor Rogers has acted as a consultant and advisor for Wyeth, Schering Plough and Abbott pharmaceuticals. Dr Kirby has acted as a consultant and advisor for Wyeth, Merck-Serono Ltd and Abbott pharmaceuticals. Copyright Journal compilation © 2009 British Association of Dermatologists ABSTRACTAim. To assess the efficacy and safety profile of adalimumab in patients with severe, recalcitrant chronic plaque psoriasis, and to assess short-term overlapping of other systemic treatment with adalimumab to prevent flaring of disease. Methods. This was a retrospective study comprising 39 patients with chronic plaque psoriasis treated with adalimumab between October 2005 and January 2008. All had failed treatment with other systemic agents, including biological therapies in 59% of patients. Patients were started on adalimumab 40 mg weekly or fortnightly, as clinically indicated. Severity of psoriasis was assessed by the Psoriasis Area and Severity Index (PASI). Therapeutic response was assessed by 75% improvement on PASI (PASI 75). All adverse events were recorded. Results. Results were analysed separately for those treated with adalimumab only and those on combination treatment. PASI 75 was achieved in 38% (8 of 21 patients at week 16), 62% (13 of 21 patients) at week 24, 69% (9 of 13 patients) at week 48% and 71% (5 of 7 patients) at week 72 in the adalimumab-only group, compared with 56% (5 of 9 patients) at week 16, 50% (4 of 8 patients) at week 24, 80% (4 of 5 patients) at week 48% and 67% (2 of 3 patients) at week 72 in the combined group. Of the 39 patients, 15 (38%) achieved a PASI of 0 at some point in their treatment. Adalimumab was well tolerated; 38% of patients experienced side-effects, which were generally mild. Conclusion. Adalimumab was effective in a group of patients with psoriasis refractory to other systemic therapies, including biological treatments, and was well tolerated. Accepted for publication 1 September 2008 | 
|
